ATE235257T1 - Zusammensetzung für behandlung von maligner tumore und ihre metastase - Google Patents

Zusammensetzung für behandlung von maligner tumore und ihre metastase

Info

Publication number
ATE235257T1
ATE235257T1 AT95940764T AT95940764T ATE235257T1 AT E235257 T1 ATE235257 T1 AT E235257T1 AT 95940764 T AT95940764 T AT 95940764T AT 95940764 T AT95940764 T AT 95940764T AT E235257 T1 ATE235257 T1 AT E235257T1
Authority
AT
Austria
Prior art keywords
tumor
lactose
cytotoxic
metastasis
malignant tumors
Prior art date
Application number
AT95940764T
Other languages
English (en)
Inventor
David Rubin
Original Assignee
Co Enzyme Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Co Enzyme Technology Ltd filed Critical Co Enzyme Technology Ltd
Application granted granted Critical
Publication of ATE235257T1 publication Critical patent/ATE235257T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95940764T 1994-12-21 1995-11-27 Zusammensetzung für behandlung von maligner tumore und ihre metastase ATE235257T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/360,352 US5639737A (en) 1991-11-04 1994-12-21 Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
PCT/US1995/015097 WO1996019243A1 (en) 1994-12-21 1995-11-27 Composition for treatment of malignant tumors and their metastases

Publications (1)

Publication Number Publication Date
ATE235257T1 true ATE235257T1 (de) 2003-04-15

Family

ID=23417628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940764T ATE235257T1 (de) 1994-12-21 1995-11-27 Zusammensetzung für behandlung von maligner tumore und ihre metastase

Country Status (8)

Country Link
US (1) US5639737A (de)
EP (1) EP0797453B1 (de)
AT (1) ATE235257T1 (de)
AU (1) AU692021B2 (de)
CA (1) CA2208206C (de)
DE (1) DE69530109T2 (de)
IL (1) IL116465A (de)
WO (1) WO1996019243A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074643A (en) * 1993-09-09 2000-06-13 Cli Oncology, Inc. Site-directed chemotherapy of metastases
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
CA2337690C (en) * 1998-07-27 2013-10-01 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
EP1261340B1 (de) 1999-07-13 2009-05-13 Alpha Research Group, LLC Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US6548484B1 (en) * 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
US9302982B2 (en) 2000-04-12 2016-04-05 Glycon Llc Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US7345031B2 (en) * 2000-04-12 2008-03-18 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US20060189547A1 (en) * 2000-04-12 2006-08-24 Christian Samuel T Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use
EP1363673A2 (de) 2000-09-25 2003-11-26 Pro-Pharmaceuticals, Inc. Zusammensetzung zur herabsetzung der nebenwirkungen in behandlungen mit chemotherapeutika
WO2002083660A1 (en) * 2001-04-10 2002-10-24 Takara Bio Inc. Remedies
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040058865A1 (en) * 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US8198328B2 (en) 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
US20060210514A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin protection and moisturizing compositions and method of making the same
WO2007025282A2 (en) * 2005-08-24 2007-03-01 Cedars-Sinai Medical Center Use of fructose-based compounds for the diagnosis of cancer
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
EP1993613A2 (de) * 2006-03-15 2008-11-26 Mallinckrodt, Inc. Chelatkonjugate mit einem substituierten aromatischen anteil und derivate davon
WO2022112596A1 (en) 2020-11-30 2022-06-02 Cellectis Sa Use of aminoquinoline compounds for higher gene integration
CN114712521B (zh) * 2022-03-22 2024-06-21 郑州大学 一种靶向cd44受体的药物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584368A (en) * 1978-10-13 1986-04-22 Adolf W. Schwimmer β-Glucuronidase activity and/or pH-dependent pharmaceuticals and thier methods of production
US4424348A (en) * 1978-10-13 1984-01-03 Adolf W. Schwimmer Methods of manufacture of nitrile-containing glucuronic acid conjugates
US4337760A (en) * 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4481195A (en) * 1978-10-13 1984-11-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US5225542A (en) * 1984-10-23 1993-07-06 Max-Planck Gesellschaft Zur Foerderung Der Wissenschaften E.V. Specific carbohydrate-binding proteins (lectins) of mammalian tumor cells
US5395924A (en) * 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
ES2058070T3 (es) * 1986-05-09 1994-11-01 Pulverer Gerhard Utilizacion de monosacaridos especificos para la preparacion de un medicamento para impedir metastasis de tumores malignos.
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
JPH06501008A (ja) * 1990-08-30 1994-01-27 ザ　バイオメンブレン　インスティテュート オリゴ糖あるいはオリゴ糖抗原または抗体による転移能および侵襲性の抑制
MX9206309A (es) * 1991-11-04 1994-05-31 David Rubin Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa.
JPH05339148A (ja) * 1992-05-28 1993-12-21 T Knight Albert 血液脳関門を通過する物質

Also Published As

Publication number Publication date
EP0797453A1 (de) 1997-10-01
DE69530109T2 (de) 2004-02-05
CA2208206C (en) 2008-02-12
AU4240796A (en) 1996-07-10
CA2208206A1 (en) 1996-06-27
DE69530109D1 (de) 2003-04-30
EP0797453B1 (de) 2003-03-26
MX9704727A (es) 1998-06-30
AU692021B2 (en) 1998-05-28
IL116465A0 (en) 1996-03-31
WO1996019243A1 (en) 1996-06-27
US5639737A (en) 1997-06-17
IL116465A (en) 2010-04-29

Similar Documents

Publication Publication Date Title
ATE235257T1 (de) Zusammensetzung für behandlung von maligner tumore und ihre metastase
Laske et al. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
Shiah et al. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl) methacrylamide copolymer–doxorubicin/mesochlorin e6-OV-TL 16 antibody immunoconjugates
Goff et al. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model
Maris et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
TR200202231T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
CA2118032A1 (en) Therapeutic conjugates of toxins and drugs
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
BR9713197A (pt) Meios para tratamento de hipertrofia de próstata e câncer de próstata
KR950031106A (ko) 종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물
Kranjc et al. Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
Pearson et al. Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice
Philpott et al. Improved selective cytotoxicity with an antibody-diphtheria toxin conjugate
Abbas et al. Antibody‐Drug Conjugates Used in Breast Cancers
ATE411051T1 (de) Polypeptid, dessen konjugat doxorubicin enthält, und auf diesem basierende pharmazeutische zusammensetzung
JPS63301832A (ja) イムノグロブリン結合体
Epstein et al. Use of the immunotoxin N901‐blocked ricin in patients with small‐cell lung cancer
Belfi et al. Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI
Wen et al. In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties